Stock 4507 SHIONOGI & CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Shionogi & Co., Ltd.

Equities

4507

JP3347200002

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-04-23 am EDT 		5-day change 1st Jan Change
7,343 JPY +1.05% Intraday chart for Shionogi & Co., Ltd. +1.46% +8.02%
Apr. 19 Shionogi & Co Completes Cancellation of 10.84 Million Treasury Shares MT
Apr. 18 Shionogi & Co., Ltd. Announces New Data from the European Real-World Evidence Study of Fetroja®/F etcroja® (cefiderocol) CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Shionogi & Co., Ltd. - Notice regarding introduction of a Restricted Stock Compensation Plan for Vice Presidents
AQ
Shionogi & Co., Ltd. - Notice Regarding Completion of Cancellation of Treasury Shares
AQ
ESCMID Global 2024, Shionogi presents real-world data demonstrating efficacy of Fetcroja, Fetroja in critically ill patients with certain difficult-to-treat bacterial infections
AQ
Shionogi & Co Completes Cancellation of 10.84 Million Treasury Shares
MT
Shionogi & Co., Ltd. Announces New Data from the European Real-World Evidence Study of Fetroja®/F etcroja® (cefiderocol)
CI
Shionogi - The European Commission Grants Orphan Medicinal Product Designation for Zatolmilast, a Potential First-In-Class Treatment Being Investigated for Fragile X Syndrome
AQ
Shionogi Completes Up to 75 Billion Yen Share Buyback
MT
Tranche Update on Shionogi & Co., Ltd.'s Equity Buyback Plan announced on July 31, 2023.
CI
Final dividend
FA
Shionogi & Co., Ltd.'s Equity Buyback announced on July 31, 2023, has closed with 10,842,100 shares, representing 3.73% for ¥74,999.22 million.
CI
FunPep Company Limited announced that it has received ¥199.9998 million in funding from Shionogi & Co., Ltd.
CI
Shionogi & Co., Ltd. - Recognized as One of the Highest-Ranking Companies on the Supplier Engagement Rating by CDP for the Fourth Consecutive Year
AQ
GSK Unit ViiV Healthcare's Injectable HIV Treatment Shows 'Superior Efficacy' in Late-stage Trial
MT
Shionogi & Co., Ltd. - Notice Regarding the Status of Acquisition of Own Shares
AQ
Shionogi Announces Xocova Obtained Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection
AQ
Shionogi Buys Back Shares Worth Nearly 12 Billion Yen
MT
ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses | GSK
AQ
GSK says ViiV's cabotegravir study supports longer HIV dose interval
AN
GSK's ViiV Healthcare Says Four-month Interval Between Doses Possible for HIV Treatment Cabotegravir
MT
Shionogi & Co., Ltd. Announces Xocova Obtains Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4507 Stock
  4. News Shionogi & Co., Ltd.